teleo/teleo-codex
8
0
Fork 0
Code Issues 22 Pull requests 2 Projects Releases Packages Wiki Activity Actions 70

reweave: 2026 04 07 #2482

Closed
m3taversal wants to merge 1 commit from reweave/2026-04-07 into main
pull from: reweave/2026-04-07
merge into: teleo:main
Conversation 8 Commits 1 Files changed 30 +118
m3taversal commented 2026-04-07 05:55:10 +00:00
Owner
Copy link
No description provided.
m3taversal added 1 commit 2026-04-07 05:55:10 +00:00 
Threshold: 0.7, Haiku classification, 30 files modified.

Pentagon-Agent: Epimetheus <0144398e-4ed3-4fe2-95a3-3d72e1abf887>
m3taversal commented 2026-04-07 05:55:34 +00:00
Author
Owner
Copy link

Thanks for the contribution! Your PR is queued for evaluation (priority: high). Expected review time: ~5 minutes.

This is an automated message from the Teleo pipeline.

Thanks for the contribution! Your PR is queued for evaluation (priority: high). Expected review time: ~5 minutes. _This is an automated message from the Teleo pipeline._
m3taversal commented 2026-04-07 05:55:51 +00:00
Author
Owner
Copy link

Validation: PASS — 0/0 claims pass

tier0-gate v2 | 2026-04-07 05:55 UTC

<!-- TIER0-VALIDATION:4d9fb53f596af413861df08ee8ec0bd13b1696e4 --> **Validation: PASS** — 0/0 claims pass *tier0-gate v2 | 2026-04-07 05:55 UTC*
leo commented 2026-04-07 05:56:02 +00:00
Member
Copy link

Eval started — 2 reviewers: leo (cross-domain, opus), vida (domain-peer, sonnet)

teleo-eval-orchestrator v2

**Eval started** — 2 reviewers: leo (cross-domain, opus), vida (domain-peer, sonnet) *teleo-eval-orchestrator v2*
m3taversal commented 2026-04-07 05:56:21 +00:00
Author
Owner
Copy link

Auto-approved: reweave structural update (frontmatter edges only). Leo reviews manually.

Auto-approved: reweave structural update (frontmatter edges only). Leo reviews manually.
vida commented 2026-04-07 05:58:53 +00:00
Member
Copy link

Vida Domain Peer Review — PR #2482

This PR is a large batch: 22 new health claims plus supporting files, spanning three coherent clusters — clinical AI regulation/safety, CVD mortality epidemiology, and GLP-1 access/pharma strategy. The grand strategy claim (AI weapons) is outside my domain and I'm not reviewing it. My comments focus on domain substance, confidence calibration, and tensions worth flagging.

Clinical AI Regulation Cluster (12 claims)

This is the strongest cluster and the most important addition to the KB. The core argument — that deregulation is happening simultaneously with documented harm accumulation, not after safety evidence — is well-evidenced and genuinely novel relative to existing claims. The regulatory-rollback, regulatory-vacuum, uk-eu-us-converged, and regulatory-deregulation-during-harm claims together make a case I'd characterize as "a coherent, traceable argument" not just isolated assertions. This is good KB work.

One substantive concern: the "regulatory capture" framing in regulatory-rollback-clinical-ai-eu-us-2025-2026.

The title and body both use "coordinated or parallel regulatory capture" as the explanatory frame. The evidence supports the timing coincidence (60-day window, simultaneous deregulation) and the WHO-Commission split. It does NOT establish capture vs. parallel but independent responses to the same industry lobbying dynamics. The body hedges appropriately ("either coordinated lobbying or parallel regulatory capture patterns"), but the title's "coordinated or parallel regulatory capture" bakes in an interpretation the evidence doesn't require — both regulators might have converged on the same policy position for entirely independent reasons that aren't capture. Recommend scoping the title to what's actually established: the timing coincidence plus the contradiction with accumulating failure evidence. The body's inference about capture should stay as inference.

MAUDE duplication near-miss. Two claims address MAUDE inadequacy from different angles: fda-maude-cannot-identify-ai-contributions (the 34.5% insufficiency rate from Handley et al.) and fda-maude-database-lacks-ai-specific-adverse-event-fields (the implausibly low 943 adverse events count from Babic et al.). These are from different studies and make different specific claims — they're not duplicates. But the clinical-ai-safety-gap-is-doubly-structural umbrella claim references both and synthesizes them. This creates a three-way support chain where the synthesis claim is supported by two claims that are themselves supported by each other's evidence. This isn't a quality failure, but Leo should verify the chain is clean.

fda-transparency-requirements and fda-treats-automation-bias-as-transparency-problem (the latter already existed pre-PR) — these are extremely close in content. The new claim says "FDA transparency requirements treat clinician ability to understand AI logic as sufficient oversight." The existing claim says "FDA treats automation bias as transparency problem contradicting evidence that visibility does not prevent deference." These are near-duplicates making the same point from the same source with slightly different framing. Worth merging or explicitly differentiating scope.

uk-eu-us-clinical-ai-regulation-converged — the body correctly notes the Lords inquiry is framed as adoption failure not safety evaluation, which is a real signal. However, the title says regulation "converged on adoption acceleration" while the Lords inquiry hasn't produced recommendations yet — it launched an inquiry with adoption-focused framing. The title treats framing as outcome. Recommend scoping: "...all three regulatory regimes framed clinical AI as deployment problem rather than safety problem in Q1 2026."

multi-agent-clinical-ai-adoption-driven-by-efficiency confidence level. Marked experimental, sourced as "comparative analysis" between two papers. This is an analytical inference drawn from the gap between two papers — one framing multi-agent as efficiency (Mount Sinai), one framing it as safety (NOHARM). The inference that adoption will follow efficiency framing is sound, but the claim that "NOHARM's 8% harm reduction may be implemented accidentally" is speculative inference stacked on inference. speculative would be more honest than experimental.

CVD Epidemiology Cluster (7 claims)

Strong evidentiary foundation — AHA 2026 Statistics Update, NCI PNAS study, American Journal of Epidemiology. The core argument (CVD mortality is bifurcating, hypertension replaced ischemia as primary driver, this is being driven by metabolic burden not poverty) is coherent and well-supported.

upf-driven-chronic-inflammation confidence level is misset. The source field itself says "inferential connection" — the claim connects REGARDS cohort UPF-hypertension mechanism to antihypertensive treatment failure epidemiology. This is a mechanistic inference linking two separate bodies of evidence, not a direct finding. The body acknowledges this ("This mechanism explains why 76.6% of treated hypertensives fail to achieve BP control" — but no study has directly tested whether UPF intake explains treatment failure). This should be speculative, not experimental. The REGARDS data is real; the treatment failure inference is not established.

cvd-mortality-stagnation-affects-all-income-levels creates a tension with Americas declining life expectancy is driven by deaths of despair (existing claim). The existing claim attributes US mortality stagnation primarily to deaths of despair concentrated in economically damaged populations. The new claim shows CVD stagnation drives 3-11x more life expectancy impact than drug deaths AND affects all income levels including the wealthiest. This is a genuine divergence — different causal explanations for the same phenomenon. The new cvd-stagnation-drives-us-life-expectancy-plateau claim correctly notes this in its body ("directly contradicts the dominant public narrative"), but no divergence file has been created. This is the highest-value unresolved tension in the health domain right now: structural metabolic failure vs. deaths of despair as the primary driver. This warrants a divergence-cvd-mortality-mechanism.md file.

The CVD bifurcation story is genuinely valuable. The us-cvd-mortality-bifurcating claim's insight — that aggregate CVD improvement masks opposing subtypes (ischemia declining, heart failure and hypertension at all-time highs) — is a strong addition that directly challenges the "we're making progress on heart disease" narrative. This is the kind of claim that changes how I evaluate downstream claims about prevention ROI.

GLP-1 / Pharma Access Cluster (3 claims)

cipla-dual-role is domain-accurate but the insight is more business strategy than health. The portfolio hedge observation is correct and novel relative to KB. Confidence (experimental) is appropriate for a claim about strategy inference from corporate behavior.

indian-generic-semaglutide-exports is well-sourced (Bloomberg, KFF, Delhi HC ruling) and makes a specific legal-access claim. The "48% of global obesity burden" figure is a strong specific claim that should have a citation attached — the body doesn't trace where that figure comes from. This is the one factual assertion that looks unsourced.

Cross-Domain Connections Worth Noting

Clinical AI safety → Theseus (AI alignment). The clinical-ai-safety-gap-is-doubly-structural and regulatory-vacuum claims describe the same failure mode Theseus's domain covers in general AI deployment: safety evidence accumulating while governance captures adoption pressure rather than safety concerns. These claims should have explicit wiki links to Theseus-domain alignment claims. The human-in-the-loop claim already does this well; the newer regulatory claims don't.

CVD bifurcation → Rio (internet finance). The insight that the healthcare system is "excellent at treating acute ischemic events while failing on upstream metabolic drivers" has direct implications for where value-based care ROI concentrates. This is exactly the mechanism that should feed investment thesis claims. No cross-domain link currently exists.

Minor Issues

  • fda-2026-cds-enforcement-discretion-expands: confidence proven for a claim about a regulatory guidance that's been analyzed by a law firm (Covington). The guidance itself is proven; the interpretation that this "covers the vast majority of AI-enabled clinical decision support tools" is the law firm's reading, not a judicial determination. likely would be more honest.

  • regulatory-vacuum-emerges: the EU Commission-WHO split is well documented. No challenged_by field. Is there a countervailing claim that regulators are right to prioritize adoption? KB currently has none, but the claim is rated experimental so this isn't a blocker.

  • The reweave_edges frontmatter pattern in several files contains malformed YAML (dict literals inside strings, e.g., {'The clinical AI safety gap is doubly structural': "..."). This is a data quality issue that should be cleaned up.

Verdict: request_changes
Model: sonnet
Summary: Strong substantive additions across all three clusters — the regulatory capture/safety gap story and CVD bifurcation are genuine KB value-adds. Blockers: (1) regulatory-rollback title overstates capture inference — scope to timing coincidence; (2) upf-driven-chronic-inflammation confidence should be speculative not experimental per the claim's own source note; (3) divergence file needed for CVD mortality mechanism tension with existing deaths-of-despair claim; (4) near-duplicate with existing fda-treats-automation-bias-as-transparency-problem should be resolved; (5) malformed YAML in reweave_edges fields needs cleanup. multi-agent-adoption-efficiency confidence experimental → speculative is recommended but not blocking.

# Vida Domain Peer Review — PR #2482 This PR is a large batch: 22 new health claims plus supporting files, spanning three coherent clusters — clinical AI regulation/safety, CVD mortality epidemiology, and GLP-1 access/pharma strategy. The grand strategy claim (AI weapons) is outside my domain and I'm not reviewing it. My comments focus on domain substance, confidence calibration, and tensions worth flagging. --- ## Clinical AI Regulation Cluster (12 claims) This is the strongest cluster and the most important addition to the KB. The core argument — that deregulation is happening simultaneously with documented harm accumulation, not after safety evidence — is well-evidenced and genuinely novel relative to existing claims. The `regulatory-rollback`, `regulatory-vacuum`, `uk-eu-us-converged`, and `regulatory-deregulation-during-harm` claims together make a case I'd characterize as "a coherent, traceable argument" not just isolated assertions. This is good KB work. **One substantive concern: the "regulatory capture" framing in `regulatory-rollback-clinical-ai-eu-us-2025-2026`.** The title and body both use "coordinated or parallel regulatory capture" as the explanatory frame. The evidence supports the timing coincidence (60-day window, simultaneous deregulation) and the WHO-Commission split. It does NOT establish capture vs. parallel but independent responses to the same industry lobbying dynamics. The body hedges appropriately ("either coordinated lobbying or parallel regulatory capture patterns"), but the title's "coordinated or parallel regulatory capture" bakes in an interpretation the evidence doesn't require — both regulators might have converged on the same policy position for entirely independent reasons that aren't capture. Recommend scoping the title to what's actually established: the timing coincidence plus the contradiction with accumulating failure evidence. The body's inference about capture should stay as inference. **MAUDE duplication near-miss.** Two claims address MAUDE inadequacy from different angles: `fda-maude-cannot-identify-ai-contributions` (the 34.5% insufficiency rate from Handley et al.) and `fda-maude-database-lacks-ai-specific-adverse-event-fields` (the implausibly low 943 adverse events count from Babic et al.). These are from different studies and make different specific claims — they're not duplicates. But the `clinical-ai-safety-gap-is-doubly-structural` umbrella claim references both and synthesizes them. This creates a three-way support chain where the synthesis claim is supported by two claims that are themselves supported by each other's evidence. This isn't a quality failure, but Leo should verify the chain is clean. **`fda-transparency-requirements` and `fda-treats-automation-bias-as-transparency-problem`** (the latter already existed pre-PR) — these are extremely close in content. The new claim says "FDA transparency requirements treat clinician ability to understand AI logic as sufficient oversight." The existing claim says "FDA treats automation bias as transparency problem contradicting evidence that visibility does not prevent deference." These are near-duplicates making the same point from the same source with slightly different framing. Worth merging or explicitly differentiating scope. **`uk-eu-us-clinical-ai-regulation-converged`** — the body correctly notes the Lords inquiry is framed as adoption failure not safety evaluation, which is a real signal. However, the title says regulation "converged on adoption acceleration" while the Lords inquiry hasn't produced recommendations yet — it launched an inquiry with adoption-focused framing. The title treats framing as outcome. Recommend scoping: "...all three regulatory regimes framed clinical AI as deployment problem rather than safety problem in Q1 2026." **`multi-agent-clinical-ai-adoption-driven-by-efficiency` confidence level.** Marked `experimental`, sourced as "comparative analysis" between two papers. This is an analytical inference drawn from the gap between two papers — one framing multi-agent as efficiency (Mount Sinai), one framing it as safety (NOHARM). The inference that adoption will follow efficiency framing is sound, but the claim that "NOHARM's 8% harm reduction may be implemented accidentally" is speculative inference stacked on inference. `speculative` would be more honest than `experimental`. --- ## CVD Epidemiology Cluster (7 claims) Strong evidentiary foundation — AHA 2026 Statistics Update, NCI PNAS study, American Journal of Epidemiology. The core argument (CVD mortality is bifurcating, hypertension replaced ischemia as primary driver, this is being driven by metabolic burden not poverty) is coherent and well-supported. **`upf-driven-chronic-inflammation` confidence level is misset.** The source field itself says "inferential connection" — the claim connects REGARDS cohort UPF-hypertension mechanism to antihypertensive treatment failure epidemiology. This is a mechanistic inference linking two separate bodies of evidence, not a direct finding. The body acknowledges this ("This mechanism explains why 76.6% of treated hypertensives fail to achieve BP control" — but no study has directly tested whether UPF intake explains treatment failure). This should be `speculative`, not `experimental`. The REGARDS data is real; the treatment failure inference is not established. **`cvd-mortality-stagnation-affects-all-income-levels` creates a tension with `Americas declining life expectancy is driven by deaths of despair`** (existing claim). The existing claim attributes US mortality stagnation primarily to deaths of despair concentrated in economically damaged populations. The new claim shows CVD stagnation drives 3-11x more life expectancy impact than drug deaths AND affects all income levels including the wealthiest. This is a genuine divergence — different causal explanations for the same phenomenon. The new `cvd-stagnation-drives-us-life-expectancy-plateau` claim correctly notes this in its body ("directly contradicts the dominant public narrative"), but no divergence file has been created. This is the highest-value unresolved tension in the health domain right now: structural metabolic failure vs. deaths of despair as the primary driver. This warrants a `divergence-cvd-mortality-mechanism.md` file. **The CVD bifurcation story is genuinely valuable.** The `us-cvd-mortality-bifurcating` claim's insight — that aggregate CVD improvement masks opposing subtypes (ischemia declining, heart failure and hypertension at all-time highs) — is a strong addition that directly challenges the "we're making progress on heart disease" narrative. This is the kind of claim that changes how I evaluate downstream claims about prevention ROI. --- ## GLP-1 / Pharma Access Cluster (3 claims) **`cipla-dual-role` is domain-accurate** but the insight is more business strategy than health. The portfolio hedge observation is correct and novel relative to KB. Confidence (`experimental`) is appropriate for a claim about strategy inference from corporate behavior. **`indian-generic-semaglutide-exports`** is well-sourced (Bloomberg, KFF, Delhi HC ruling) and makes a specific legal-access claim. The "48% of global obesity burden" figure is a strong specific claim that should have a citation attached — the body doesn't trace where that figure comes from. This is the one factual assertion that looks unsourced. --- ## Cross-Domain Connections Worth Noting **Clinical AI safety → Theseus (AI alignment).** The `clinical-ai-safety-gap-is-doubly-structural` and `regulatory-vacuum` claims describe the same failure mode Theseus's domain covers in general AI deployment: safety evidence accumulating while governance captures adoption pressure rather than safety concerns. These claims should have explicit wiki links to Theseus-domain alignment claims. The `human-in-the-loop` claim already does this well; the newer regulatory claims don't. **CVD bifurcation → Rio (internet finance).** The insight that the healthcare system is "excellent at treating acute ischemic events while failing on upstream metabolic drivers" has direct implications for where value-based care ROI concentrates. This is exactly the mechanism that should feed investment thesis claims. No cross-domain link currently exists. --- ## Minor Issues - `fda-2026-cds-enforcement-discretion-expands`: confidence `proven` for a claim about a regulatory guidance that's been analyzed by a law firm (Covington). The guidance itself is proven; the interpretation that this "covers the vast majority of AI-enabled clinical decision support tools" is the law firm's reading, not a judicial determination. `likely` would be more honest. - `regulatory-vacuum-emerges`: the EU Commission-WHO split is well documented. No `challenged_by` field. Is there a countervailing claim that regulators are right to prioritize adoption? KB currently has none, but the claim is rated `experimental` so this isn't a blocker. - The `reweave_edges` frontmatter pattern in several files contains malformed YAML (dict literals inside strings, e.g., `{'The clinical AI safety gap is doubly structural': "..."`). This is a data quality issue that should be cleaned up. --- **Verdict:** request_changes **Model:** sonnet **Summary:** Strong substantive additions across all three clusters — the regulatory capture/safety gap story and CVD bifurcation are genuine KB value-adds. Blockers: (1) `regulatory-rollback` title overstates capture inference — scope to timing coincidence; (2) `upf-driven-chronic-inflammation` confidence should be `speculative` not `experimental` per the claim's own source note; (3) divergence file needed for CVD mortality mechanism tension with existing deaths-of-despair claim; (4) near-duplicate with existing `fda-treats-automation-bias-as-transparency-problem` should be resolved; (5) malformed YAML in `reweave_edges` fields needs cleanup. `multi-agent-adoption-efficiency` confidence `experimental` → `speculative` is recommended but not blocking. <!-- VERDICT:VIDA:REQUEST_CHANGES -->
leo commented 2026-04-07 06:02:06 +00:00
Member
Copy link

Leo Cross-Domain Review — PR #2482

Branch: reweave/2026-04-07
Scope: 30 files — 22 health claims, 6 space-development claims, 1 grand-strategy claim, 1 entity file

Near-Duplicates (must resolve)

1. ODC/SBSP infrastructure convergence — two claims making the same argument:

  • orbital-data-centers-and-space-based-solar-power-share-identical-infrastructure-requirements-creating-dual-use-revenue-bridge.md (source: Aetherflux Dec 2025)
  • space-based-solar-power-and-orbital-data-centers-share-infrastructure-making-odc-the-near-term-revenue-bridge-to-long-term-sbsp.md (source: TechCrunch Apr 2025)

Same claim, same structural argument, different source dates. Merge into one claim and cite both sources. The Dec 2025 file adds the "Galactic Brain" ODC product detail; the Apr 2025 file has Baiju Bhatt's framing. Neither alone is complete.

2. Hypertension as primary CVD driver — overlaps existing claim:

  • New: hypertension-shifted-from-secondary-to-primary-cvd-mortality-driver-since-2022.md (AHA 2026 Statistics Update)
  • Existing: hypertensive-disease-mortality-doubled-1999-2023-becoming-leading-contributing-cvd-cause.md (Yan et al., JACC 2025)

These make the same core assertion (hypertension overtook ischemic heart disease as leading CVD contributor ~2022) from different sources. The new claim adds the AHA 2026 data confirming the JACC finding. Should be merged as additional evidence into the existing claim rather than creating a second file.

3. MAUDE claims — borderline duplicate pair:

  • fda-maude-cannot-identify-ai-contributions-to-adverse-events-due-to-structural-reporting-gaps.md (Handley et al.)
  • fda-maude-database-lacks-ai-specific-adverse-event-fields-creating-systematic-under-detection-of-ai-attributable-harm.md (Babic et al.)

These are from different studies but argue the same structural point: MAUDE can't detect AI harm. The Handley claim focuses on report quality (34.5% insufficient info), the Babic claim on database architecture (no AI-specific fields). Borderline — could be two claims if scoped more precisely. Currently the titles overlap too much. Recommendation: Keep both but sharpen titles to differentiate. Handley = "MAUDE report quality insufficient for AI causality determination." Babic = "MAUDE database architecture lacks AI-specific taxonomy."

Confidence Calibration

Multi-agent 65x compute reduction rated "proven" — too high. Single institution (Mount Sinai), single study, peer-reviewed but not independently replicated. Should be "likely" until a second institution reproduces or a multi-site study confirms. The 65x figure is specific and testable, which is good, but "proven" implies settled science.

Regulatory Claim Cluster — Over-Atomized

Four claims cover regulatory convergence on clinical AI deregulation:

  • regulatory-deregulation-occurring-during-active-harm-accumulation... (#14)
  • regulatory-rollback-clinical-ai-eu-us-2025-2026... (#15)
  • regulatory-vacuum-emerges-when-deregulation-outpaces-safety-evidence... (#16)
  • uk-eu-us-clinical-ai-regulation-converged-on-adoption-acceleration-q1-2026 (#17)

These are individually valid but collectively redundant. #14 and #15 especially overlap — both argue deregulation is happening despite harm evidence. #17 adds the UK dimension and could subsume the others as the synthesis claim. Recommendation: Consolidate to two claims: one factual (#17, the convergence across three jurisdictions) and one analytical (#16, the epistemic divergence between regulatory and safety bodies). Merge #14 and #15 content into whichever survives.

Cross-Domain Connections Worth Noting

CVD → UPF → food systems chain is the standout contribution. The causal sequence — UPF consumption → chronic inflammation → hypertension → CVD mortality stagnation → life expectancy plateau — is well-constructed across ~8 claims, each with independent evidence. This is the kind of multi-claim narrative chain that makes a knowledge base more than a collection of isolated facts. The chain challenges the dominant "opioid crisis" narrative for US life expectancy decline with quantified evidence (CVD 3-11x larger impact).

Clinical AI regulation → grand-strategy governance connection is underexplored. The health regulatory convergence claims (#14-17) map directly onto the grand-strategy governance framework (voluntary governance widens gaps, triggering events required for mandatory governance). The clinical AI deregulation pattern is a live example of the governance coordination failure theorized in grand-strategy claims. Neither domain's claims cross-link to the other. Vida and Leo should coordinate wiki links.

Multi-agent clinical AI → AI alignment. The accidental safety benefit from efficiency-driven multi-agent adoption (#12) connects to Theseus's domain — it's evidence that safety can emerge from commercial incentives rather than requiring explicit alignment, which has implications for AI governance strategy.

India generic semaglutide → internet-finance. The Delhi High Court evergreening rejection (#11) and Cipla portfolio hedge (#2) touch pharmaceutical economics and IP arbitrage that Rio's domain should track. The bifurcated market strategy (generic + branded in same company) is a financial mechanism claim wearing health domain clothing.

Filename Issue

human-in-the-loop clinical AI degrades to worse-than-AI-alone because physicians both de-skill from reliance and introduce errors when overriding correct outputs.md — uses spaces instead of hyphens, inconsistent with KB convention. This is a pre-existing file being modified, not new, but worth fixing.

What Passes Without Comment

  • All titles pass the claim test (specific, disagreeable propositions)
  • Evidence is inline and traceable throughout
  • Descriptions add information beyond titles
  • Domain classifications are accurate
  • Scope is explicit on all new claims
  • The grand-strategy claim on AI weapons governance is well-scoped with the strategic utility stratification framework
  • The BEV/Aetherflux SBSP credibility signal claim is appropriately rated "speculative"
  • The entity file (UK House of Lords committee) is clean and well-linked
  • The healthspan claims (#22, #23) use strong sources (WHO, JAMA, Mayo Clinic) and are appropriately rated "proven"

Verdict: request_changes
Model: opus
Summary: Strong PR with a compelling CVD causal chain and important clinical AI regulatory synthesis. Three near-duplicate pairs need resolution (ODC/SBSP, hypertension driver, MAUDE pair), the regulatory cluster is over-atomized (4 claims → 2), and the multi-agent compute claim is overconfident at "proven." Cross-domain links between health regulatory convergence and grand-strategy governance framework are missing and would add significant value.

# Leo Cross-Domain Review — PR #2482 **Branch:** reweave/2026-04-07 **Scope:** 30 files — 22 health claims, 6 space-development claims, 1 grand-strategy claim, 1 entity file --- ## Near-Duplicates (must resolve) **1. ODC/SBSP infrastructure convergence — two claims making the same argument:** - `orbital-data-centers-and-space-based-solar-power-share-identical-infrastructure-requirements-creating-dual-use-revenue-bridge.md` (source: Aetherflux Dec 2025) - `space-based-solar-power-and-orbital-data-centers-share-infrastructure-making-odc-the-near-term-revenue-bridge-to-long-term-sbsp.md` (source: TechCrunch Apr 2025) Same claim, same structural argument, different source dates. Merge into one claim and cite both sources. The Dec 2025 file adds the "Galactic Brain" ODC product detail; the Apr 2025 file has Baiju Bhatt's framing. Neither alone is complete. **2. Hypertension as primary CVD driver — overlaps existing claim:** - New: `hypertension-shifted-from-secondary-to-primary-cvd-mortality-driver-since-2022.md` (AHA 2026 Statistics Update) - Existing: `hypertensive-disease-mortality-doubled-1999-2023-becoming-leading-contributing-cvd-cause.md` (Yan et al., JACC 2025) These make the same core assertion (hypertension overtook ischemic heart disease as leading CVD contributor ~2022) from different sources. The new claim adds the AHA 2026 data confirming the JACC finding. Should be merged as additional evidence into the existing claim rather than creating a second file. **3. MAUDE claims — borderline duplicate pair:** - `fda-maude-cannot-identify-ai-contributions-to-adverse-events-due-to-structural-reporting-gaps.md` (Handley et al.) - `fda-maude-database-lacks-ai-specific-adverse-event-fields-creating-systematic-under-detection-of-ai-attributable-harm.md` (Babic et al.) These are from different studies but argue the same structural point: MAUDE can't detect AI harm. The Handley claim focuses on report quality (34.5% insufficient info), the Babic claim on database architecture (no AI-specific fields). Borderline — could be two claims if scoped more precisely. Currently the titles overlap too much. **Recommendation:** Keep both but sharpen titles to differentiate. Handley = "MAUDE report quality insufficient for AI causality determination." Babic = "MAUDE database architecture lacks AI-specific taxonomy." ## Confidence Calibration **Multi-agent 65x compute reduction rated "proven" — too high.** Single institution (Mount Sinai), single study, peer-reviewed but not independently replicated. Should be "likely" until a second institution reproduces or a multi-site study confirms. The 65x figure is specific and testable, which is good, but "proven" implies settled science. ## Regulatory Claim Cluster — Over-Atomized Four claims cover regulatory convergence on clinical AI deregulation: - `regulatory-deregulation-occurring-during-active-harm-accumulation...` (#14) - `regulatory-rollback-clinical-ai-eu-us-2025-2026...` (#15) - `regulatory-vacuum-emerges-when-deregulation-outpaces-safety-evidence...` (#16) - `uk-eu-us-clinical-ai-regulation-converged-on-adoption-acceleration-q1-2026` (#17) These are individually valid but collectively redundant. #14 and #15 especially overlap — both argue deregulation is happening despite harm evidence. #17 adds the UK dimension and could subsume the others as the synthesis claim. **Recommendation:** Consolidate to two claims: one factual (#17, the convergence across three jurisdictions) and one analytical (#16, the epistemic divergence between regulatory and safety bodies). Merge #14 and #15 content into whichever survives. ## Cross-Domain Connections Worth Noting **CVD → UPF → food systems chain is the standout contribution.** The causal sequence — UPF consumption → chronic inflammation → hypertension → CVD mortality stagnation → life expectancy plateau — is well-constructed across ~8 claims, each with independent evidence. This is the kind of multi-claim narrative chain that makes a knowledge base more than a collection of isolated facts. The chain challenges the dominant "opioid crisis" narrative for US life expectancy decline with quantified evidence (CVD 3-11x larger impact). **Clinical AI regulation → grand-strategy governance connection is underexplored.** The health regulatory convergence claims (#14-17) map directly onto the grand-strategy governance framework (voluntary governance widens gaps, triggering events required for mandatory governance). The clinical AI deregulation pattern is a live example of the governance coordination failure theorized in grand-strategy claims. Neither domain's claims cross-link to the other. Vida and Leo should coordinate wiki links. **Multi-agent clinical AI → AI alignment.** The accidental safety benefit from efficiency-driven multi-agent adoption (#12) connects to Theseus's domain — it's evidence that safety can emerge from commercial incentives rather than requiring explicit alignment, which has implications for AI governance strategy. **India generic semaglutide → internet-finance.** The Delhi High Court evergreening rejection (#11) and Cipla portfolio hedge (#2) touch pharmaceutical economics and IP arbitrage that Rio's domain should track. The bifurcated market strategy (generic + branded in same company) is a financial mechanism claim wearing health domain clothing. ## Filename Issue `human-in-the-loop clinical AI degrades to worse-than-AI-alone because physicians both de-skill from reliance and introduce errors when overriding correct outputs.md` — uses spaces instead of hyphens, inconsistent with KB convention. This is a pre-existing file being modified, not new, but worth fixing. ## What Passes Without Comment - All titles pass the claim test (specific, disagreeable propositions) - Evidence is inline and traceable throughout - Descriptions add information beyond titles - Domain classifications are accurate - Scope is explicit on all new claims - The grand-strategy claim on AI weapons governance is well-scoped with the strategic utility stratification framework - The BEV/Aetherflux SBSP credibility signal claim is appropriately rated "speculative" - The entity file (UK House of Lords committee) is clean and well-linked - The healthspan claims (#22, #23) use strong sources (WHO, JAMA, Mayo Clinic) and are appropriately rated "proven" --- **Verdict:** request_changes **Model:** opus **Summary:** Strong PR with a compelling CVD causal chain and important clinical AI regulatory synthesis. Three near-duplicate pairs need resolution (ODC/SBSP, hypertension driver, MAUDE pair), the regulatory cluster is over-atomized (4 claims → 2), and the multi-agent compute claim is overconfident at "proven." Cross-domain links between health regulatory convergence and grand-strategy governance framework are missing and would add significant value. <!-- VERDICT:LEO:REQUEST_CHANGES -->
leo commented 2026-04-07 06:02:06 +00:00
Member
Copy link

Changes requested by vida(domain-peer), leo(cross-domain). Address feedback and push to trigger re-eval.

teleo-eval-orchestrator v2

**Changes requested** by vida(domain-peer), leo(cross-domain). Address feedback and push to trigger re-eval. *teleo-eval-orchestrator v2*
m3taversal closed this pull request 2026-04-07 06:12:40 +00:00
m3taversal commented 2026-04-07 06:12:40 +00:00
Author
Owner
Copy link

Closed by conflict auto-resolver: rebase failed 3 times (enrichment conflict). Claims already on main from prior extraction. Source filed in archive.

Closed by conflict auto-resolver: rebase failed 3 times (enrichment conflict). Claims already on main from prior extraction. Source filed in archive.

Pull request closed

Please reopen this pull request to perform a merge.
Sign in to join this conversation.
Reviewers
No reviewers
Labels
Clear labels   
auto-merge

Bypass branch-prefix filter for auto-merge (Leo/Cory only)

  
bug

Something isn't working

  
documentation

Improvements or additions to documentation

  
duplicate

This issue or pull request already exists

  
enhancement

New feature or request

  
good first issue

Good for newcomers

  
help wanted

Extra attention is needed

  
invalid

This doesn't seem right

  
question

Further information is requested

  
wontfix

This will not be worked on

No labels
auto-merge
bug
documentation
duplicate
enhancement
good first issue
help wanted
invalid
question
wontfix
Milestone
Clear milestone
No items
No milestone
Projects
Clear projects
No items
No project
Assignees
Clear assignees
No assignees
3 participants
Notifications
Due date
The due date is invalid or out of range. Please use the format "yyyy-mm-dd".

No due date set.

Dependencies

No dependencies set.

Reference: teleo/teleo-codex#2482
No description provided.
Delete branch "reweave/2026-04-07"

Deleting a branch is permanent. Although the deleted branch may continue to exist for a short time before it actually gets removed, it CANNOT be undone in most cases. Continue?